Endocrinology Today—April 28, 2026

LucidQuest

3 hours ago

This week’s Endocrinology update highlights regulatory actions, clinical progress, reimbursement developments, and pipeline activity across diabetes, obesity, growth disorders, and bone health.

In Today’s Newsletter

Dive deeper

💉 Biocon denosumab biosimilars approved [1] [Canada • 22 Apr 2026]

https://vohnetwork.com/news/pharma/biocon-secures-health-canada-approval-for-denosumab-biosimilars-bosaya-and-vevzuo
Context: Bosaya is a Prolia biosimilar; Vevzuo is an Xgeva biosimilar, with indications across osteoporosis and cancer-related bone conditions.
Key point: Biocon said Health Canada granted NOCs for Bosaya (denosumab) and Vevzuo (denosumab) on 03 Apr 2026.
Implication: Introduces competition that may affect pricing and formulary access.

🧬 Lonapegsomatropin extension supports adult GHD use [2] [US • 22 Apr 2026]

https://www.hcplive.com/view/lonapegsomatropin-proves-long-term-benefit-for-adult-ghd-in-phase-3-foresight-extension-trial
Context: The Phase 3 program randomized 259 adults; 220 entered extension and 202 completed 52 extension weeks.
Key point: Ascendis Pharma’s lonapegsomatropin (Skytrofa) showed long-term safety and efficacy signals in the foresiGHt extension.
Implication: May influence prescriber choice and payer reviews pending full data.

🍽️ Novo Nordisk oral semaglutide hits youth T2D endpoint [3] [US/EU • 23 Apr 2026]

https://www.biospace.com/press-releases/novo-nordisks-oral-semaglutide-demonstrates-potential-to-be-the-first-oral-glp-1-ra-therapy-for-children-and-adolescents-with-type-2-diabetes
Context: PIONEER TEENS is a Phase 3a trial in children and adolescents aged 10–17 years with type 2 diabetes.
Key point: Novo Nordisk said oral semaglutide reduced HbA1c by 0.83% versus placebo at 26 weeks in PIONEER TEENS.
Implication: May influence prescriber choice and payer reviews pending full data.

⚖️ Antag Therapeutics to present AT7687 data at ADA 2026 [4] [US • 23 Apr 2026]

https://www.biospace.com/press-releases/antag-therapeutics-to-present-data-on-at7687-its-first-in-class-gipr-antagonist-peptide-at-the-american-diabetes-associations-2026-scientific-sessions
Context: The company will also present preclinical data combining AT7687 with cagrilintide in obese insulin-resistant non-human primates.
Key point: Antag Therapeutics will present first-in-human AT7687 data at ADA 2026, including healthy subjects and people living with obesity.
Implication: Signals pipeline investment and modality expansion.

🛡️ FDA expands Tzield to younger children [5] [US • 23 Apr 2026]

https://www.endocrinologyadvisor.com/news/tzield-approved-to-delay-stage-3-type-1-diabetes-in-younger-children/
Context: Approval was based on PETITE-T1D, a single-arm, open-label Phase 4 study in 23 children with stage 2 type 1 diabetes.
Key point: FDA expanded Tzield (teplizumab-mzwv) to delay stage 3 type 1 diabetes in children aged 1 to less than 8 years.
Implication: May expand screening, initiation, and follow-up at scale.

🇰🇷 Korea reviews Ozempic and diabetes reimbursement rules [6] [Korea • 27 Apr 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31435 Context: KDA said proposed changes could broaden access based on cardiovascular, kidney, and heart-failure risks.
Key point: Korea’s health authorities are reviewing reimbursement rules that may restrict access to newer diabetes drugs, including Ozempic.
Implication: Could inform practice and payer discussions; interpretation depends on policy design and implementation.

💊 Ascletis completes ASC30 diabetes Phase II enrollment [7] [US • 27 Apr 2026]

https://firstwordpharma.com/story/7209803
Context: The randomized, double-blind, placebo-controlled study enrolled 100 participants and tests once-daily oral ASC30 tablets.
Key point: Ascletis completed enrollment in a 13-week US Phase II study of ASC30 in type 2 diabetes.
Implication: Signals pipeline investment and modality expansion.

🇮🇳 Sun Pharma semaglutide shows comparability in India Phase III [8] [India • 27 Apr 2026]

https://medicaldialogues.in/diabetes-endocrinology/news/efficacy-and-safety-of-injectable-semaglutide-in-indian-patients-with-type-2-diabetes-findings-from-a-phase-iii-study-presented-at-ids-2026-169469
Context: The open-label Phase III study randomized 314 patients and followed treatment for 24 weeks.
Key point: Sun Pharma’s injectable semaglutide was reported non-inferior to reference Ozempic in Indian adults with uncontrolled type 2 diabetes.
Implication: Introduces competition that may affect pricing and formulary access.

Why It Matters

GLP-1 development is widening across age groups, regions, and formulations, from Novo Nordisk’s oral semaglutide in youth to Ascletis’ oral small-molecule ASC30.
Access and reimbursement remain central, with Korea reviewing Ozempic restrictions and Biocon adding denosumab biosimilars in Canada.
Type 1 diabetes prevention is moving earlier, as Tzield’s FDA label now includes children as young as 1 year with stage 2 disease.
Obesity pipelines continue to diversify beyond GLP-1, including Antag Therapeutics’ GIPR antagonist AT7687.
Local comparability evidence matters, as Sun Pharma’s semaglutide study targets Indian patients and reference-product equivalence.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What did Health Canada approve for Biocon?

Health Canada approved Bosaya (denosumab), a Prolia biosimilar, and Vevzuo (denosumab), an Xgeva biosimilar. Biocon said the products target osteoporosis and cancer-related bone conditions. [1]

What is new for Novo Nordisk’s oral semaglutide in PIONEER TEENS?

Novo Nordisk reported positive topline Phase 3a data in children and adolescents aged 10–17 years with type 2 diabetes. The company said it expects US and EU regulatory filings in the second half of 2026. [3]

What is AT7687 from Antag Therapeutics?

AT7687 is Antag Therapeutics’ first-in-class GIPR antagonist peptide for obesity. ADA 2026 presentations will include first-in-human data and preclinical combination data with cagrilintide. [4]

How did FDA expand Tzield use?

FDA expanded Tzield (teplizumab-mzwv) for pediatric patients aged 1 to less than 8 years with stage 2 type 1 diabetes to delay stage 3 disease. The label includes a longer minimum infusion time for younger children. [5]

What is Korea reviewing for Ozempic access?

Korean authorities are reviewing diabetes drug reimbursement rules that KDA says may limit access to newer treatments, including Ozempic. Possible revisions could consider heart, kidney, and other clinical risks. [6]

What did Sun Pharma report for injectable semaglutide in India?

Sun Pharma’s injectable semaglutide was reported non-inferior to reference Ozempic in a Phase III Indian study, with comparable glycemic, weight, and safety findings. [8]

Entities / Keywords

Biocon: Bosaya, Vevzuo, denosumab, Prolia biosimilar, Xgeva biosimilar, Health Canada
Ascendis Pharma: lonapegsomatropin, Skytrofa, TransCon hGH, foresiGHt, adult growth hormone deficiency
Novo Nordisk: oral semaglutide, Rybelsus, Ozempic pill, PIONEER TEENS, pediatric type 2 diabetes
Antag Therapeutics: AT7687, GIPR antagonist, cagrilintide, obesity, ADA 2026
Sanofi: Tzield, teplizumab-mzwv, stage 2 type 1 diabetes, stage 3 type 1 diabetes, PETITE-T1D
Korean Diabetes Association: KDA, Ozempic, semaglutide, NHIS, Ministry of Health and Welfare, reimbursement
Ascletis Pharma: ASC30, oral small-molecule GLP-1R agonist, type 2 diabetes, obesity
Sun Pharma: injectable semaglutide, Ozempic comparator, Indian Phase III, IDS 2026